Conference Overview
Competitive threats, industry dynamics and regulation are some of the most important factors driving change for pharma and life sciences CEOs according to the PwC CEO survey 2011.
Whilst the global market for medicines is growing, the global economy is forcing businesses to rethink their strategies if they are to capitalise on the opportunities available.
The major trends sited by PwC reshaping the marketplace include:
- The soaring burden of chronic disease;
- healthcare policy-makers and payers mandating what doctors can prescribe;
- healthcare payers measuring the pharmacoeconomic performance of different medicines;
- boundaries blurring across healthcare;
- demand for medicines is growing faster in the emerging economies than the industrialised economies;
- governments are beginning to re-focus their attention from treatment to prevention; and
- the regulators are becoming more cautious about approving truly innovative medicines.
These trends all compound the challenges we already face, yet for the brave they are providing major opportunities.
At the 2012 Biopharmaceutical Conference in Europe we hear from the brave, the pioneers who are embracing the changes and shaping the future for their businesses. We ask them to share their vision and how they intend to turn vision to reality and either remain as, or become the leading businesses of tomorrow.
As always The Biopharmaceutical Conference in Europe is an exclusive by invitation only meeting, where biotech CEOs from around the world can gather with senior executives from major Bio-Pharmaceutical companies.
